The all-new continuous glucose monitor from Abbott Laboratories is now available at participating retail pharmacies and durable medical equipment suppliers. The Freestyle Libre 3 was approved by the FDA in June and is an advancement over previous Abbott systems.

Abbott Laboratories and Dexcom are the leaders in the CGM market, which reached $5.1 billion in revenue in 2021 and is expected to reach $13.2 billion by 2028, according to Vantage Market Research. Abbott's CGM systems, called FreeStyle Libre, generated $3.7 billion in revenue last year, with 4 million users worldwide.

CNBC's Erin Black, a type 1 diabetic, tested the Libre 3 for over a month. Here is his review.

» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision

About CNBC: From 'Wall Street' to 'Main Street' to award-winning original documentaries and reality series, CNBC has you covered. Discover special previews of your favorite shows, exclusive videos and much more.

Connect with CNBC News Online
Get the latest news: https://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

#CNBC

Abbott Freestyle Libre 3 Review – A Discreet CGM for Diabetics

Please take the opportunity to connect and share this video with your friends and family if you find it useful.